<DOC>
	<DOCNO>NCT00905632</DOCNO>
	<brief_summary>The main purpose clinical trial BI 207127 see effect 4 week combination BI 207127 Peginterferon alfa ( Peg-IFN ) Ribavirin ( RBV ) hepatitis C virus ( HCV ) virus load safe BI 207127 combination HCV infect patient .</brief_summary>
	<brief_title>4 Week Combination BI 207127 NA With Peg-IFN Ribavirin Chronic HCV Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Inclusion criterion : 1 . HCV genotype 1 2 . HCV viral load &gt; 100,000 IU/mL 3. histology fibroscan rule cirrhosis 4 . Absence retinopathy 5. treatment naive patient treatment experience patient 6 . Age 18 70 year 7 . Male OR female document hysterectomy OR postmenopausal Exclusion criterion : 1 . Fertile male willing use adequate form contraception 2 . Pretreatment HCVpolymerase inhibitor 3 . Any concurrent disease clinically significant base investigator 's medical assessment 4 . Current alcohol drug abuse , history 5 . Positive test HIV HBs 6 . History malignancy 7 . Planned concurrent usage pharmacological therapy include antiviral therapy vaccination 8 . Usage investigational drug within thirty ( 30 ) day prior enrolment 5 halflives , whichever longer 9 . Any clinically significant laboratory abnormality base investigator 's medical assessment screen 10 . Patients treat interferon ( approved investigational ) PegIFN and/or Ribavirin within 3 month prior screen 11 . Known hypersensitivity drug excipients ; Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>